Kang, Jisoo Jeong, Hwajun Jeong, Minseok Kim, Jaehoon Park, Sungnam Jung, Junyang An, Jong Min Kim, Dokyoung 2024-01-25T05:01:05Z 2024-01-25T05:01:05Z 2024-01-25 2023-12 0002-7863 https://pubs.kist.re.kr/handle/201004/148466 Photodynamic therapy (PDT) has been used to reduce cancerous and precancerous cells via reactive oxygen species (ROS) generation from photosensitizers. Numerous photosensitizers are available today to treat a variety of diseases, but their therapeutic efficacy is hindered within the tumor microenvironment, and there are safety concerns associated with their non-specific activation. In this work, we disclosed a nano-therapeutic based on in situ activatable nitrobenzene-cysteine-copper-(II) nano-complexes (NCCNs) that work within cancer cells. Among the NCCNs, CyP shows outstanding potential as a promising candidate for programmed photodynamic cancer therapy with its unique properties such as (i) bright near-infrared imaging, (ii) chemodynamic therapeutic effect, (iii) photodynamic therapeutic effect (types I and II), and (iv) anti-cancer effect by anti-angiogenesis in early cancer stage under light. Overall, this work opens up exciting possibilities for the development of innovative and effective treatments for cancer, paving the way for future advancements in the clinical medicine field. English American Chemical Society In Situ Activatable Nitrobenzene-Cysteine-Copper(II) Nano-complexes for Programmed Photodynamic Cancer Therapy Article 10.1021/jacs.3c09339 1 Journal of the American Chemical Society, v.145, no.50, pp.27587 - 27600 Journal of the American Chemical Society 145 50 27587 27600 N scie scopus 001143029300001 2-s2.0-85179499120 Chemistry, Multidisciplinary Chemistry Article VISIBLE-LIGHT OXIDATION NANOPARTICLES GLUTATHIONE STRATEGIES SYSTEMS THIOLS H2O2 IRON